Nanollose Ltd
ASX:NC6

Watchlist Manager
Nanollose Ltd Logo
Nanollose Ltd
ASX:NC6
Watchlist
Price: 0.05 AUD 8.7% Market Closed
Market Cap: 15.8m AUD
Section:
 

Relative Value

NC6 doesn't have a meaningful market cap.

The Relative Value of one NC6 stock under the Base Case scenario is hidden AUD. Compared to the current market price of 0.05 AUD, Nanollose Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

NC6 Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

1 271.1
P/S
P/S
Price to Sales
1 271.1
vs History
30
vs Industry
7
Median 3Y
198.5
Median 5Y
1 016.9
Industry
8
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-4.8
Median 5Y
-6.2
Industry
23.5
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-6
Median 5Y
-8.1
Industry
21.9
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-7.6
Median 5Y
-9.6
Industry
24.3
More Details
38.5
P/B
P/B
Price to Book Value
38.5
vs History
1
vs Industry
3
Median 3Y
11.9
Median 5Y
7.4
Industry
3.2
More Details
1 219.7
EV/S
EV/S
Enterprise Value to Sales
1 219.7
vs History
30
vs Industry
6
Median 3Y
191.2
Median 5Y
965.5
Industry
8.1
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.1
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-4.8
Median 5Y
-6.1
Industry
5.9
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-4.8
Median 5Y
-6.1
Industry
6.2
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
Median 3Y
-5.4
Median 5Y
-6.9
Industry
7.7
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-5.4
Median 5Y
-6.9
Industry
6.3
More Details
Negative
EV/IC
EV/IC
Enterprise Value to IC
N/A
vs History
vs Industry
3
Median 3Y
-45.3
Median 5Y
-14
Industry
5.6
More Details

Multiples Across Competitors

NC6 Competitors Multiples
Nanollose Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
Nanollose Ltd
ASX:NC6
15.3m AUD 1 271.1 -10.7 -10.5 -10.5
IL
Can Fite Biopharma Ltd
TASE:CANF
707T ILS 255 217 482.5 -17 526 694.5 -17 199 054.4 -17 160 769.7
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 944 814.2 -161 334.7 -195 911.8 -193 676.2
US
Abbvie Inc
NYSE:ABBV
395.8B USD 6.6 168.6 16.3 23.2
US
Amgen Inc
NASDAQ:AMGN
177.6B USD 4.9 25.4 18.3 18.3
US
Gilead Sciences Inc
NASDAQ:GILD
150.7B USD 5.2 18.6 12.5 12.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119B USD 10.1 32.4 23.8 24.8
US
Epizyme Inc
F:EPE
94.1B EUR 2 075.4 -529.6 -576.7 -561.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
81.8B USD 5.7 17.9 17.1 19.3
AU
CSL Ltd
ASX:CSL
82.3B AUD 3.6 18.5 12.5 15.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
53.6B USD 16.7 1 229.4 165.8 201.1
P/S Multiple
Revenue Growth P/S to Growth
AU
Nanollose Ltd
ASX:NC6
Average P/S: 26 287 790.6
1 271.1
N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
255 217 482.5
140%
1 822 982
FR
Pharnext SCA
OTC:PNEXF
33 944 814.2
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.6
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.9
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.2
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.1
10%
1
US
E
Epizyme Inc
F:EPE
2 075.4
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.7
6%
1
AU
CSL Ltd
ASX:CSL
3.6
5%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.7
46%
0.4
P/E Multiple
Earnings Growth PEG
AU
Nanollose Ltd
ASX:NC6
Average P/E: 215.8
Negative Multiple: -10.7 		N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -17 526 694.5 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -161 334.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
168.6
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25.4
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.6
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
32.4
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -529.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.9
10%
1.8
AU
CSL Ltd
ASX:CSL
18.5
11%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 229.4
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
AU
Nanollose Ltd
ASX:NC6
Average EV/EBITDA: 38
Negative Multiple: -10.5 		N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -17 199 054.4 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 911.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.3
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.3
11%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.8
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -576.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.1
11%
1.6
AU
CSL Ltd
ASX:CSL
12.5
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
165.8
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
AU
Nanollose Ltd
ASX:NC6
Average EV/EBIT: 45
Negative Multiple: -10.5 		N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -17 160 769.7 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -193 676.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.2
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.3
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.8
16%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -561.3 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.3
13%
1.5
AU
CSL Ltd
ASX:CSL
15.6
11%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
201.1
N/A N/A

See Also

Summary
NC6 intrinsic value, competitors valuation, and company profile.
DCF Valuation
NC6 stock valuation using Discount Cash Flow valuation method.
Relative Valuation
NC6 stock valuation using valuation multiples.
Wall Street Estimates
NC6 price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
NC6 stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 307,800+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.